Physician profile
Melvin C Chen
NPI 1194772574
$4,268.17
in general payments reported to CMS, 2019-2025
20 companies · $46.36 in 2025
The $46.36 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,862 · 2020: $134 · 2021: $247 · 2022: $761 · 2023: $631 · 2024: $586 · 2025: $46.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,246 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,246.04 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,283.99 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $488.09 | 2019-2024 | Ultomiris, Soliris |
| Regeneron Healthcare Solutions, INC. | $466.43 | 2019-2024 | Eylea Hd |
| Genentech USA, INC. | $438.80 | 2019-2024 | Vabysmo, Lucentis |
| Abbvie INC. | $415.89 | 2022-2025 | Botox, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $268.66 | 2019-2021 | |
| Horizon Therapeutics Plc | $238.68 | 2020-2023 | Tepezza |
| Amgen INC. | $137.59 | 2019-2025 | Tepezza |
| Apellis Pharmaceuticals, INC. | $121.85 | 2022 | |
| Ani Pharmaceuticals, INC. | $86.66 | 2024 | Purified Cortrophin Gel |
| Sun Pharmaceutical Industries INC. | $77.09 | 2021-2024 | |
| Allergan, INC. | $71.34 | 2020-2022 | |
| Coherus Oncology, INC. | $35.48 | 2023 | |
| Merz North America, INC. | $32.35 | 2020 | |
| Merz Pharmaceuticals, LLC | $29.42 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $22.70 | 2020-2023 | Yutiq |
| Ucb, INC. | $18.72 | 2023 | |
| Bausch & Lomb Americas INC. | $17.84 | 2024 | Miebo |
| Harrow Eye, LLC | $16.59 | 2024 | Vevye |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melvin Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.